Related Experiment Video

Updated: May 28, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Exploiting nature's rich source of proteasome inhibitors as starting points in drug development

Melissa Ann Gräwert1, Michael Groll

  • 1Center for Integrated Protein Science at the Department Chemie, Lehrstuhl für Biochemie, Technische Universität München, Lichtenbergstrasse 4, 85748 Garching, Germany. melissa.graewert@tum.de

Chemical Communications (Cambridge, England)
|November 1, 2011
PubMed

Insights

Proteasome inhibitors, inspired by natural compounds, offer promising cancer treatments. Structural studies reveal binding mechanisms, enabling drug optimization for reduced side effects and broader applications.

Area of Science:

  • Biochemistry
  • Medicinal Chemistry
  • Pharmacology

Background:

  • Cancer is a leading cause of death and a significant economic burden, driving pharmaceutical research for effective treatments.
  • Velcade® (bortezomib), a proteasome inhibitor, validated the proteasome as a cancer target, achieving blockbuster status for multiple myeloma treatment.
  • Despite Velcade®'s success, its toxicity necessitates the development of improved proteasome inhibitors.

Purpose of the Study:

  • To review the structural elucidation of proteasome inhibitors and their binding mechanisms.
  • To highlight the optimization of natural products into potential therapeutic agents.
  • To discuss the diverse applications of proteasome inhibitors beyond oncology.

Main Methods:

  • Review of scientific literature on proteasome inhibitors.
  • Analysis of structural data and binding mechanisms.
  • Examination of medicinal chemistry strategies for drug optimization.

Main Results:

  • Natural products serve as a foundation for developing potent proteasome inhibitors.
  • Understanding unique binding mechanisms allows for the design of drugs with improved efficacy and safety profiles.
  • Proteasome inhibitors show therapeutic potential in multiple myeloma, other cancers, and various non-oncological conditions.

Conclusions:

  • The proteasome remains a validated and important target for drug development.
  • Structural insights into natural proteasome inhibitors are crucial for medicinal chemistry efforts.
  • Optimized proteasome inhibitors offer a promising avenue for reduced off-target effects and expanded therapeutic applications.

More Related Videos

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources10:24

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources

Published on: January 27, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...